{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:42Z","timestamp":1781646762553,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ewing sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Tumor-associated macrophages (TAMs) are a key component of the tumor microenvironment. While increased TAMs infiltration is linked to poor prognosis in various solid tumors, limited data are available regarding their role in sarcomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study aimed to evaluate the frequency, density, and prognostic impact of TAMs in pediatric patients with ES treated at the Pediatric Oncology Department, National Cancer Institute (NCI), Cairo University. Immunohistochemical analysis of CD68 and CD163 expression was performed on 74 tumor tissue samples from pediatric patients with ES, which helps us understand the density of TAMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study cohort comprised 74 patients with a median age of 12 years (range: 0.5\u201318 years) and a male-to-female ratio of 0.8:1. The 5-year overall survival (OS) and event-free survival (EFS) rates were 48% and 42.8%, respectively. CD68 expression showed significant correlations with age at diagnosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035) and tumor size (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031) and near-significant associations with skeletal tumor location (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.052) and complete response following induction chemotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.054). CD163 expression was significantly associated with age at diagnosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046). However, neither CD68 (\u2264\u200960 vs.\u2009&gt;\u200960) nor CD163 (\u2264\u200990 vs.\u2009&gt;\u200990) levels showed significant correlation with survival outcomes (OS or EFS). Initial primary tumor site, tumor stage, post-induction chemotherapy disease status, and histological response to induction chemotherapy were significant predictor of survival outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TAM markers (CD68 and CD163) did not demonstrate a significant prognostic impact on survival. Larger-scale studies are warranted to more precisely determine the role of TAMs in pediatric ES.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04295-6","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:27:49Z","timestamp":1774621669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of tumor-associated macrophages in pediatric Ewing sarcoma, National Cancer Institute (2010\u20132020)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7058-4406","authenticated-orcid":false,"given":"Mustafa Mohamed","family":"Selim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Ragab","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahitab Ibrahim","family":"Eltohamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-6290","authenticated-orcid":false,"given":"Nesreen Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"6","key":"4295_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPH.0b013e31816e22f3","volume":"30","author":"N Esiashvili","year":"2008","unstructured":"Esiashvili N, Goodman M, Marcus RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol. 2008;30(6):425\u201330. https:\/\/doi.org\/10.1097\/MPH.0b013e31816e22f3.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"4295_CR2","doi-asserted-by":"publisher","first-page":"E508","DOI":"10.1002\/ijc.26426","volume":"131","author":"J Whelan","year":"2012","unstructured":"Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, et al. Incidence and survival of malignant bone sarcomas in England 1979\u20132007. Int J Cancer. 2012;131(4):E508\u201317. https:\/\/doi.org\/10.1002\/ijc.26426.","journal-title":"Int J Cancer"},{"key":"4295_CR3","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/OTT.S170585","volume":"12","author":"D Van Mater","year":"2019","unstructured":"Van Mater D, Wagner L. Management of recurrent Ewing sarcoma: Challenges and approaches. OncoTargetsTher. 2019;12:2279\u201388. https:\/\/doi.org\/10.2147\/OTT.S170585.","journal-title":"OncoTargetsTher"},{"issue":"1","key":"4295_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5507\/BP.2017.049","volume":"162","author":"M Handl","year":"2018","unstructured":"Handl M, Hermanova M, Hotarkova S, Jarkovsky J, Mudry P, Shatokhina T, et al. Clinicopathological correlation of tumor-associated macrophages in Ewing sarcoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(1):54\u201360. https:\/\/doi.org\/10.5507\/BP.2017.049.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"4295_CR5","doi-asserted-by":"publisher","first-page":"581107","DOI":"10.3389\/fonc.2020.581107","volume":"10","author":"J Koo","year":"2020","unstructured":"Koo J, Hayashi M, Verneris MR, Lee-Sherick AB. Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment. Front Oncol. 2020;10:581107. https:\/\/doi.org\/10.3389\/fonc.2020.581107.","journal-title":"Front Oncol"},{"issue":"1","key":"4295_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58. https:\/\/doi.org\/10.1186\/s13045-017-0430-2.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"4295_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"4295_CR8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers12071987","volume":"12","author":"AM Malfitano","year":"2020","unstructured":"Malfitano AM, Pisanti S, Napolitano F, Di Somma S, Martinelli R, Portella G. Tumor-associated macrophage status in cancer treatment. Cancers (Basel). 2020;12(7):1987. https:\/\/doi.org\/10.3390\/cancers12071987.","journal-title":"Cancers (Basel)"},{"key":"4295_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","volume":"119","author":"A Le Cesne","year":"2019","unstructured":"Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, Penel N, et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019;119:151\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.018.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4295_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/cancers13051086","volume":"13","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara T, Healey J, Ogura K, Yoshida A, Kondo H, Hata T, et al. Role of Tumor-Associated Macrophages in Sarcomas. Cancers (Basel). 2021;13(5):1086. https:\/\/doi.org\/10.3390\/cancers13051086.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4295_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694\u2013701.","journal-title":"N Engl J Med"},{"issue":"2","key":"4295_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4295_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jso.21237","volume":"99","author":"FL Greene","year":"2009","unstructured":"Greene FL, Sobin LH. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol. 2009;99(5):269\u201372. https:\/\/doi.org\/10.1002\/jso.21237.","journal-title":"J Surg Oncol"},{"issue":"12","key":"4295_CR14","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE. 2012;7(12):e50946. https:\/\/doi.org\/10.1371\/journal.pone.0050946.","journal-title":"PLoS ONE"},{"issue":"3","key":"4295_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.ajpath.2011.05.034","volume":"179","author":"T Fujiwara","year":"2011","unstructured":"Fujiwara T, Fukushi JI, Yamamoto S, Matsumoto Y, Setsu N, Oda Y. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol. 2011;179(3):1157\u201370. https:\/\/doi.org\/10.1016\/j.ajpath.2011.05.034.","journal-title":"Am J Pathol"},{"issue":"11","key":"4295_CR16","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/sj.bjc.6603774","volume":"96","author":"YS Lau","year":"2007","unstructured":"Lau YS, Adamopoulos IE, Sabokbar A, Giele H, Gibbons CLMH, Athanasou NA. Cellular and humoral mechanisms of osteoclast formation in Ewing\u2019s sarcoma. Br J Cancer. 2007;96(11):1716\u201322. https:\/\/doi.org\/10.1038\/sj.bjc.6603774.","journal-title":"Br J Cancer"},{"issue":"12","key":"4295_CR17","doi-asserted-by":"publisher","first-page":"e1674113","DOI":"10.1080\/2162402X.2019.1674113","volume":"8","author":"D Stahl","year":"2019","unstructured":"Stahl D, Gentles AJ, Thiele R, G\u00fctgemann I. Prognostic profiling of the immune cell microenvironment in Ewing\u2019s Sarcoma Family of Tumors. Oncoimmunology. 2019;8(12):e1674113. https:\/\/doi.org\/10.1080\/2162402X.2019.1674113.","journal-title":"Oncoimmunology"},{"key":"4295_CR18","doi-asserted-by":"publisher","first-page":"100619","DOI":"10.1016\/j.jbo.2024.100619","volume":"47","author":"S \u00c7akmakc\u0131","year":"2024","unstructured":"\u00c7akmakc\u0131 S, Sar\u0131 N, Atasever Akka\u015f E, Y\u0131ld\u0131z F, Karakaya E, Kaya B, et al. Real-world experiences in patients with Ewing sarcoma treated at a specialist centre in Turkey. J Bone Oncol. 2024;47:100619. https:\/\/doi.org\/10.1016\/j.jbo.2024.100619.","journal-title":"J Bone Oncol"},{"issue":"1","key":"4295_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/08880018.2021.1931588","volume":"39","author":"AM Mahmoud","year":"2022","unstructured":"Mahmoud AM, Zekri W, Khorshed EN, Shalaby LM. Prognostic significance of survivin expression in pediatric Ewing sarcoma. Pediatr Hematol Oncol. 2022;39(1):16\u201327. https:\/\/doi.org\/10.1080\/08880018.2021.1931588.","journal-title":"Pediatr Hematol Oncol"},{"key":"4295_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00122","volume":"5","author":"SS Majeed","year":"2019","unstructured":"Majeed SS, Muhammad HA, Ali JS, Khudhair HH, Said A, Arif SO, et al. Treatment outcomes of pediatric patients with Ewing sarcoma in a war-torn nation: A single-institute experience from Iraq. J Glob Oncol. 2019;5:1\u20139. https:\/\/doi.org\/10.1200\/JGO.18.00122.","journal-title":"J Glob Oncol"},{"key":"4295_CR21","doi-asserted-by":"publisher","first-page":"101708","DOI":"10.1016\/j.cegh.2024.101708","volume":"28","author":"G Pant","year":"2024","unstructured":"Pant G, Verma N, Shukla V. Ewing\u2019s sarcoma in pediatric population of North India: Demographics, outcome & prognostic factors. Clin Epidemiol Glob Health. 2024;28:101708. https:\/\/doi.org\/10.1016\/j.cegh.2024.101708.","journal-title":"Clin Epidemiol Glob Health"},{"issue":"13","key":"4295_CR22","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1002\/cncr.25144","volume":"116","author":"AA Gupta","year":"2010","unstructured":"Gupta AA, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J, et al. Clinical outcome of children and adults with localized Ewing sarcoma. Cancer. 2010;116(13):3189\u201394. https:\/\/doi.org\/10.1002\/cncr.25144.","journal-title":"Cancer"},{"key":"4295_CR23","doi-asserted-by":"publisher","first-page":"1103565","DOI":"10.3389\/fped.2023.1103565","volume":"11","author":"CJ Hsu","year":"2023","unstructured":"Hsu CJ, Ma Y, Xiao P, Hsu CC, Wang D, Fok MN, et al. Overall survival comparison between pediatric and adult Ewing sarcoma of bone and adult nomogram construction: a large population-based analysis. Front Pediatr. 2023;11:1103565. https:\/\/doi.org\/10.3389\/fped.2023.1103565.","journal-title":"Front Pediatr"},{"issue":"4","key":"4295_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.6001\/actamedica.v24i4.3615","volume":"24","author":"G Jakutis","year":"2017","unstructured":"Jakutis G, Ragelien\u0117 L, Rascon J. Survival of children treated for Ewing sarcoma in Lithuania: a single centre experience. Acta Med Litu. 2017;24(4):199\u2013208. https:\/\/doi.org\/10.6001\/actamedica.v24i4.3615.","journal-title":"Acta Med Litu"},{"issue":"2","key":"4295_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1590\/1516-3180.2017.0236230917","volume":"136","author":"ZH Wan","year":"2017","unstructured":"Wan ZH, Huang ZH, Chen LB. Survival outcome among patients with Ewing\u2019s sarcoma of bones and joints: a population-based cohort study. Sao Paulo Med J. 2017;136(2):116\u201322. https:\/\/doi.org\/10.1590\/1516-3180.2017.0236230917.","journal-title":"Sao Paulo Med J"},{"key":"4295_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.oraloncology.2019.04.019","volume":"93","author":"G Troiano","year":"2019","unstructured":"Troiano G, Caponio VCA, Adipietro I, Tepedino M, Santoro R, Laino L, et al. Prognostic significance of CD68\u2009+\u2009and CD163\u2009+\u2009tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2019;93:66\u201375. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.04.019.","journal-title":"Oral Oncol"},{"key":"4295_CR27","doi-asserted-by":"publisher","unstructured":"Chohan MH, Perry M, Laurance-Young P, Salih VM, Foey AD. Prognostic role of CD68\u2009+\u2009and CD163\u2009+\u2009tumour-associated macrophages and PD-L1 expression in oral squamous cell carcinoma: a meta-analysis. British Journal of Biomedical Science, 80, 11065. 2023:80:11065. https:\/\/doi.org\/10.3389\/bjbs.2023.11065.","DOI":"10.3389\/bjbs.2023.11065"},{"key":"4295_CR28","doi-asserted-by":"publisher","unstructured":"Hu Y, He MY, Zhu LF, Yang CC, Zhou ML, Wang Q et al. Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Experimental Clin Cancer Res. 2016:3512. https:\/\/doi.org\/10.1186\/s13046-015-0281-z.","DOI":"10.1186\/s13046-015-0281-z"},{"issue":"6","key":"4295_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00262-021-03098-w","volume":"71","author":"M Sun","year":"2022","unstructured":"Sun M, Zeng H, Jin K, Liu Z, Hu B, Liu C, et al. Infiltration and polarization of tumor-associated macrophages predict prognosis and therapeutic benefit in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2022;71(6):1497\u2013506. https:\/\/doi.org\/10.1007\/s00262-021-03098-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"4295_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/path.4769","volume":"240","author":"O Hashimoto","year":"2016","unstructured":"Hashimoto O, Yoshida M, Koma YI, Yanai T, Hasegawa D, Kosaka Y, et al. Collaboration of cancer-associated fibroblasts and tumour\u2010associated macrophages for neuroblastoma development. J Pathol. 2016;240(2):211\u201323. https:\/\/doi.org\/10.1002\/path.4769.","journal-title":"J Pathol"},{"issue":"9","key":"4295_CR31","doi-asserted-by":"publisher","first-page":"e1331193","DOI":"10.1080\/2162402X.2017.1331193","volume":"6","author":"A Gomez-Brouchet","year":"2017","unstructured":"Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 2017;6(9):e1331193. https:\/\/doi.org\/10.1080\/2162402X.2017.1331193.","journal-title":"Oncoimmunology"},{"key":"4295_CR32","doi-asserted-by":"publisher","unstructured":"Han Q, Shi H, Liu F. CD163\u2009+\u2009M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol. 2016:34:101\u2013106;34:101\u20136. https:\/\/doi.org\/10.1016\/j.intimp.2016.01.023.","DOI":"10.1016\/j.intimp.2016.01.023"},{"issue":"10","key":"4295_CR33","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/pbc.26096","volume":"63","author":"T Cash","year":"2016","unstructured":"Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2016;63(10):1771\u20139. https:\/\/doi.org\/10.1002\/pbc.26096.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"4295_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.suronc.2018.05.016","volume":"27","author":"AD Lynch","year":"2018","unstructured":"Lynch AD, Gani F, Meyer CF, Morris CD, Ahuja N, Johnston FM. Extraskeletal versus skeletal Ewing sarcoma in the adult population: controversies in care. Surg Oncol. 2018;27(3):373\u20139. https:\/\/doi.org\/10.1016\/j.suronc.2018.05.016.","journal-title":"Surg Oncol"},{"issue":"6","key":"4295_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/jjco\/hyw032","volume":"46","author":"S Takenaka","year":"2016","unstructured":"Takenaka S, Naka N, Obata H, Joyama S, Hamada KI, Imura Y, et al. Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. Jpn J Clin Oncol. 2016;46(6):522\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyw032.","journal-title":"Jpn J Clin Oncol"},{"key":"4295_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jss.2024.09.037","volume":"303","author":"CD Fritz","year":"2024","unstructured":"Fritz CD, Basta AV, Gill J, Lewis VO, Bird JE, Austin MT. Pediatric Ewing Sarcoma Presentation, Treatment, and Outcomes Across Sociodemographic Groups. J Surg Res. 2024;303:322\u201331. https:\/\/doi.org\/10.1016\/j.jss.2024.09.037.","journal-title":"J Surg Res"},{"issue":"20","key":"4295_CR37","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","volume":"28","author":"R Ladenstein","year":"2010","unstructured":"Ladenstein R, P\u00f6tschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284\u201391. https:\/\/doi.org\/10.1200\/JCO.2009.22.9864.","journal-title":"J Clin Oncol"},{"issue":"20","key":"4295_CR38","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1002\/cncr.27493","volume":"118","author":"A Longhi","year":"2012","unstructured":"Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer. 2012;118(20):5050\u20139. https:\/\/doi.org\/10.1002\/cncr.27493. Digital Object Identifier (DOI).","journal-title":"Cancer"},{"issue":"3","key":"4295_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/cncr.29065","volume":"121","author":"SG DuBois","year":"2015","unstructured":"DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children\u2019s Oncology Group. Cancer. 2015;121(3):467\u201375. https:\/\/doi.org\/10.1002\/cncr.29065.","journal-title":"Cancer"},{"issue":"3","key":"4295_CR40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ijrobp.2006.01.019","volume":"65","author":"G Bacci","year":"2006","unstructured":"Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P. The role of surgical margins in treatment of Ewing\u2019s sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiation Oncology* Biology* Phys. 2006;65(3):766\u201372. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.01.019.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"4","key":"4295_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.suronc.2018.07.016","volume":"27","author":"SE Bosma","year":"2018","unstructured":"Bosma SE, Ayu O, Fiocco M, Gelderblom H, Dijkstra PD. Prognostic factors for survival in Ewing sarcoma: a systematic review. Surg Oncol. 2018;27(4):603\u201310. https:\/\/doi.org\/10.1016\/j.suronc.2018.07.016.","journal-title":"Surg Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04295-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:00:28Z","timestamp":1781643628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04295-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4295"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04295-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board (IRB) of NCI, Cairo University, an ethical committee (Approval number: 2204-307-017). Written informed consent was obtained from the guardians of all patients prior to the initiation of treatment. The IRB of NCI, Cairo University has approved the waiver of patient consent form because of retrospective nature of the study which used archived data and did not affect patient well-being in any way. Patient confidentiality was maintained at all time in accordance with NCI, Cairo University policies.Data collection and presentation were anonymous and both privacy and confidentiality were protected to the maximal possible standards. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki (World Medical Association, 2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}